PROSTAGLANDIN VIII - 15-METHYL-15-HYDROXY-9-OXOPROSTANOIC ACID - A POTENT ORALLY ACTIVE ANTISECRETORY AGENT

J.F. Bag!i, T. Bogri, and S.N. Sehgal

Ayerst Research Laboratories, Montreal, P.Q. Canada

(Received in USA 11 May 1973; received in UK for publication 23 July 1973)

The inhibition of the gastric acid secretion by natural prostaglandins is well documented.²
Similar activity has been reported in the prostanoic acid analogs of simpler chemical structure³
relative to the natural compounds. Prostaglandins suffer enzymatic dehydrogenation at C=15.⁴ The substrate specificity for this reaction is markedly reduced when the C=13 double bond is saturated.⁵
Assuming, that prostanoic acid analogs follow a similar pattern of metabolic fate, it was of interest to prepare simpler analogs that cannot undergo dehydrogenation at C=15.

Recently the bioconversion of prostanoic acid derivatives has been reported. 6 We wish to report the synthesis and biological profile of a 15-methyl-15-hydroxy-9-oxoprostanoic acid. The diketone 1^{7,8} was bioconverted with the resting cells of <u>Saccharomyces cerevisiae</u> (ATCC-4125). The crude extract was esterified with diazomethane and chromatographed to yield (30-40%) of a more polar product together with about the same amount of unchanged starting material. The product was isolated and characterised 9 as (+) alcohol methyl ester $\underline{2}$, (oil, Table 1). This was hydrolysed with methanolic sodium hydroxide to give acid $\underline{3}$ (crystals, mp 65-7°). The ORD spectrum of the acid $\underline{3}$ has positive cotton effect (peak 312 nm, [0] \times 10⁻³ + 2.89, trough 272 nm, [0] \times 10⁻³, -3.53; cross over 296 nm). The CD spectrum showed a positive maximum (296 nm, $[\theta] \times 10^{-3}$, +5.3). The ORD and CD spectra 10 are essentially the mirror images of those reported!! for tetrahydro PGA₁. The unchanged diketone obtained from the first bioconversion was recharged in the fermentation reaction. The diketone was recovered from this second experiment with essentially no transformation to the alcohol. This established !) that only the ent-isomer of I was selectively transformed under the reaction contitions, 2) that the alcohol 3 described above was optically free of any nat-isomer and 3) that the diketone recovered must belong to nat-series. The last inference was confirmed by the negative optical rotation (Table I), negative cotton effect (ORD) and a

negative CD minimum and this compound was assigned structure $\underline{4}$ (oil). Since chiroptical contribution of C-15 (prostanoid numbering) is expected to be very small, compared to those of chiral centers at carbons 8 and 12, it is not possible to assign unambiguously the stereochemistry in $\underline{3}$ at C-15. That the positive cotton effect of $\underline{3}$ is due to ent-trans rather than 8-epi (cis) structure 12 is supported by the recovery of the unchanged diketone as its <u>nat-isomer</u>. The optical purity of the alcohol $\underline{3}$ was further confirmed by its transformation to diketone $\underline{5}$ (oil) of <u>ent-series</u>. Oxidation of the methyl ester $\underline{2}$ with Jones reagent or with pyridine-chromic anhydride in methylene chloride gave the diketone $\underline{5}$ (89%) whose ORD and CD spectra were mirror images of those of the diketone $\underline{4}$. Thus compound $\underline{3}$ is formulated as <u>ent-tetrahydro PGA</u> or its 15-epimer. 13

Treatment of diketone $\underline{1}$, $\underline{4}$ and $\underline{5}$ (0.05 eq) in dry ether with freshly prepared methyl magnesium iodide (0.05 eq, I molar in ether) under nitrogen atmosphere at room temperature 14 gave $\underline{6}$, $\underline{10}$ and $\underline{7}$ (52.8%, based on recovered starting material) respectively as a mixture of stereoisomer 9 at C-15. The hydrolysis of these esters with methanolic sodium hydroxide gave the corresponding 15-methyl-15-hydroxy-9-oxoprostanoic acids 9 8, $\underline{11}$, $\underline{9}$ (oils) respectively.

The (\pm) 15-methyl-15-hydroxy tetrahydro PGA 8 cannot be a substrate to 15-hydroxyprostaglandin dehydrogenase enzyme 15 by virtue of the presence of the tertiary alcohol at C-15. Compound 8 produces contractions (0.08-0.09 times that of PGF $_{2\alpha}$) in the isolated rat uterus preparation in vitro. When given intravenously, to normotensive anesthetized cats it demonstrates a short lasting fall in blood pressure. The compound is weakly active in the abortifacient assay in hamsters when administered subcutaneously, compared to PGF $_{2\alpha}$.

When administered orally, the compound is a <u>potent inhibitor of gastric acid secretion</u> in rats using PGE₂ as standard. Furthermore, acid $\underline{8}$ is also <u>a potent inhibitor of ulcers</u> induced by pyloric ligation. ¹⁷

When the acids <u>9</u> and <u>11</u> obtained from the two optical enantiomers <u>7</u> and <u>10</u> were tested both in the abortifacient assay in hamsters and in the inhibition of gastric acid secretion in rats, the acid <u>9</u> of the <u>ent</u>-series was more active than the acid derived from the ester <u>10</u> belonging to the <u>nat</u>-series. Thus acid <u>9</u> represents yet another example of a prostanoic acid, belonging to the <u>int</u>-series and demonstrating potent biological activity. ¹⁸

The simplicity of structure and the retention of the biological profile, as well as a signifiant degree of dissociation between antifertility and inhibition of gastric acid secretion are the striking features of the 15-methy1-15-hydroxy-9-oxoprostanoic acid 8.

 \perp (±), Racemic

 $\underline{4}$ (-), \underline{nat}^{19} -series

2 R=H, R'=CH3(+) ent-series

3 R=R'=H (+) ent-series

6 R=R'=CH3(±)(011)

8 R=CH3, R'=H (±)

7 R=R'=CH3(+) ent-series (oil)

9 R=CH3, R'=H (+) ent-series

COOR

5 (+) ent 19-series

10, R=CH₃(-) <u>nat</u>-series (oil)

11, R=H (-) <u>nat</u>-series

Table I. Optical Rotations $(o_0^{250}, CHCI_3)^a$

Compound Nos	<u>na+</u> -	Compound Nos	ent-	
<u>4</u>	-16.8	<u>5</u>	+19.0	
<u>10</u>	-15.6	<u>2</u>	+18.3	
11	~ 20 . 4	<u>3</u>	+21.4	
		I	+13.2	
		2	+14.3	

a All rotations were done in a concentration of 0.1%

REFERENCES

- 1) For Part VI see N.A. Abraham, Tetrahedron Letters, 451 (1973).
- 2) D.E. Wilson, Prostaglandin, 1, 281 (1972).
- 3) a) W. Lippmann, J. Pharm. Pharmacol., 21, 335 (1969).
 - b) <u>idem.</u>, <u>ibid.</u>, 22, 65 (1970).
- 4) E. Anggard and B. Samuelsson, Arch. Kemi., <u>25</u>, 293 (1966).
- 5) B. Samuelsson, E. Granstrom, K. Green and M. Hamberg, Ann. N.Y. Acad. Sci., <u>180</u>, 138 (1971)
- 6) a) M. Miyano, C.R. Dorn, F.B. Colton and W.J. Marsheck, Chem. Com., 425 (1973).
 - b) W.P. Schneider and H.C. Murray, J. Org. Chem., <u>38</u>, 397 (1973).

- 7) J.F. Bagli and T. Bogri, J. Org. Chem., <u>37</u>, 2132 (1972).
- 8) Alternatively the diketone can also be obtained by hydrogenation of 9,15-dioxoprost-13-enoic acid methyl ester. [See J. Bagli and T. Bogri, Tetrahedron Letters, 3815 (1972)].
- 9) Satisfactory (a) analytical (b) spectral data was obtained for this compound.
- 10) We wish to thank Dr. Korver for recording ORD and CD spectra of acid 3.
- II) O. Korver, Rec. Trav. Chim., 88, 1071 (1969).
- 12) E.G. Daniels, W.C. Drueger, F.P. Kupiecki, J.E. Pike and W.P. Schneider, J. Amer. Chem. Soc., 90, 5894 (1968).
- 13) In view of the enzymatic nature of the reduction the possibility of a stereoisomeric mixture at C-15 is excluded.
- 14) Under these conditions no products corresponding to the attack of the Grignard reagent at C-9 ketone or C-I ester carbonyl were isolated. A by-product was however, isolated which was isomeric in its composition with the starting diketone. The structure of this product will be discussed in a later communication.
- 15) E.W. Yankee and G.L. Bundy, J. Amer. Chem. Soc., 94, 3651 (1972).
- 16) The authors wish to thank Drs. C. Revesz and G. Beaulieu for making the pharmacological data available. A detailed report of the biology of these and other analogs will appear in a later communication.
- 17) Dr. W. Lippmann, private communication.
- 18) a) J. Fried, M.M. Mehra and W.L. Kao., J. Amer. Chem. Soc., 93, 5594 (1971).
 - b) E.J. Corey, S. Terashima, P.W. Ramwell, R. Jessup, N.M. Weinshenker, D.M. Floyd and G.A. Grosby, J. Org. Chem., 37, 3043 (1972).
 - c) J. Fried and C.H. Lin, J. Med. Chem., 16, 429 (1973).
- 19) The terminology <u>nat</u>-refers to the compounds having the same absolute configuration at C-8 and C-12 as in natural prostaglandins and <u>ent</u>-refers to the antipodal series, at those carbon atoms.